Trichomonas vaginalis: a review of epidemiologic, clinical and treatment issues.
Trichomonas vaginalis: a review of epidemiologic, clinical and treatment issues.
复制标题
阴道毛滴虫：流行病学、临床和治疗问题的回顾。
DOI：
10.1186/s12879-015-1055-0
复制
发表时间：
2015-08-05
影响因子：
3.7
通讯作者：
Kissinger P
中科院分区：
文献类型：
--
作者：
Kissinger P
阴道毛滴虫（TV）是世界上最常见的非病毒性性传播感染（STI）。它是生殖疾病的一个重要来源，是艾滋病毒传播和感染的推动者，因此是一个重要的公共卫生问题。尽管它在人类生殖健康和艾滋病毒传播方面很重要，但它不是一种可报告的疾病，而且一般没有进行监测。这是有问题的，因为大多数感染电视的人是无症状的。几十年来，甲硝唑（MTZ）一直是女性的首选治疗方法，单剂量被认为是一线治疗方法。然而，在接受单剂量MTZ治疗的TV感染者中，复验阳性率很高。这不能用耐药性来解释，因为体外耐药性只有2 - 5%。在艾滋病毒阳性妇女中，治疗失败率可达7 - 10%，甚至更高。治疗效果可能受阴道生态的影响。重复阳性的来源需要进一步解释，并需要更好的治疗方案。
Trichomonas vaginalis (TV) is likely the most common non-viral sexually transmitted infection (STI) in the world. It is as an important source of reproductive morbidity, a facilitator of HIV transmission and acquisition, and thus it is an important public health problem. Despite its importance in human reproductive health and HIV transmission, it is not a reportable disease and surveillance is not generally done. This is problematic since most persons infected with TV are asymptomatic. Metronidazole (MTZ) has been the treatment of choice for women for decades, and single dose has been considered the first line of therapy. However, high rates of retest positive are found among TV infected persons after single dose MTZ treatment. This has not been explained by drug resistance since in vitro resistance is only 2–5 %. Treatment failure can range from 7–10 % and even higher among HIV+ women. Treatment efficacy may be influenced by vaginal ecology. The origins of repeat positives need further explanation and better treatment options are needed.